{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:22:55Z","timestamp":1793290975058,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2022,2,22]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>We assessed the effect of once-weekly semaglutide and once-daily liraglutide on kidney outcomes in type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Pooled (n=12\u2009637) and by-trial data from SUSTAIN 6 (Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes; n=3297) and LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; n=9340) were assessed for albuminuria change, annual slope of estimated glomerular filtration rate (eGFR) change, and time to persistent eGFR reduction (30%, 40%, 50%, and 57%) from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The median follow-up durations were 2.1 years for SUSTAIN 6 and 3.8 years for LEADER. In the pooled analysis, semaglutide\/liraglutide lowered albuminuria from baseline to 2 years after randomization by 24% versus placebo (95% CI, 20%\u201327%;\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001). Significant reductions were also observed in by-trial data analyses (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001 for all), the largest being with semaglutide 1.0 mg (33% [95% CI, 24%\u201340%];\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001) at 2 years. With semaglutide 1.0 mg and liraglutide, eGFR slope decline was significantly slowed by 0.87 and 0.26 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      \/y (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.0001 and\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001), respectively, versus placebo. Effects appeared larger in patients with baseline eGFR &lt;60 versus \u226560 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (\n                      <jats:italic>P<\/jats:italic>\n                      <jats:sub>interaction<\/jats:sub>\n                      =0.06 and 0.008 for semaglutide 1.0 mg and liraglutide, respectively). Semaglutide\/liraglutide significantly lowered risk of persistent 40% and 50% eGFR reductions versus placebo (hazard ratio [HR], 0.86 [95% CI, 0.75\u20130.99];\n                      <jats:italic>P<\/jats:italic>\n                      =0.039 and HR, 0.80 [95% CI, 0.66\u20130.97];\n                      <jats:italic>P<\/jats:italic>\n                      =0.023, respectively). Similar, nonsignificant, directional results were observed for 30% and 57% eGFR reductions (HR, 0.92 [95% CI, 0.84\u20131.02];\n                      <jats:italic>P<\/jats:italic>\n                      =0.10 and HR, 0.89 [95% CI, 0.69\u20131.13];\n                      <jats:italic>P<\/jats:italic>\n                      =0.34). In patients with baseline eGFR 30 to &lt;60 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , the likelihood of persistent reduction for all thresholds was increased, ranging from HR 0.71 for 30% reduction (95% CI, 0.59\u20130.85;\n                      <jats:italic>P<\/jats:italic>\n                      =0.0003,\n                      <jats:italic>P<\/jats:italic>\n                      <jats:sub>interaction<\/jats:sub>\n                      =0.017) to 0.54 for 57% reduction (95% CI, 0.36\u20130.81;\n                      <jats:italic>P<\/jats:italic>\n                      =0.003,\n                      <jats:italic>P<\/jats:italic>\n                      <jats:sub>interaction<\/jats:sub>\n                      =0.035).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In patients with type 2 diabetes, semaglutide\/liraglutide offered kidney-protective effects, which appeared more pronounced in patients with preexisting chronic kidney disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circulationaha.121.055459","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T05:00:14Z","timestamp":1639458014000},"page":"575-585","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":252,"title":["Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER"],"prefix":"10.1161","volume":"145","author":[{"given":"Ahmed M.","family":"Shaman","sequence":"first","affiliation":[{"name":"Sydney School of Public Health, University of Sydney, Australia (A.M.S.)."},{"name":"The George Institute for Global Health, The University of New South Wales, Sydney, Australia (A.M.S., V.P.)."},{"name":"College of Pharmacy, King Saud University, Riyadh, Saudi Arabia (A.M.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Bain","sequence":"additional","affiliation":[{"name":"Institute of Life Science, Swansea University Medical School, Singleton Hospital, Swansea, United Kingdom (S.C.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1267","authenticated-orcid":true,"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine, IL (G.L.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-3876","authenticated-orcid":true,"given":"John B.","family":"Buse","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill (J.B.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Idorn","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark (T.I., S.R., B.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"Stanford Center for Clinical Research (SCCR), Department of Medicine, Stanford School of Medicine, CA (K.W.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F.E.","family":"Mann","sequence":"additional","affiliation":[{"name":"KfH Kidney Center, Munich, Germany (J.F.E.M.)."},{"name":"Friedrich Alexander University, Erlangen, Germany (J.F.E.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Nauck","sequence":"additional","affiliation":[{"name":"Diabetes Division, Katholisches Klinikum Bochum, St Josef Hospital (Ruhr-Universit\u00e4t Bochum), Bochum, Germany (M.A.N.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark (T.I., S.R., B.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen, Gentofte, Denmark (P.R.)."},{"name":"Department of Clinical Medicine, University of Copenhagen, Denmark (P.R.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wolthers","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark (T.I., S.R., B.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Zinman","sequence":"additional","affiliation":[{"name":"Lunenfeld\u2013Tanenbaum Research Institute, Mt Sinai Hospital, University of Toronto, Canada (B.Z.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4257-7620","authenticated-orcid":true,"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, The University of New South Wales, Sydney, Australia (A.M.S., V.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2017.10.011"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1296"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.4103\/2468-8827.184853"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61601-9"},{"key":"e_1_3_2_6_2","unstructured":"United States Renal Data System. Annual data report: chapter 7: healthcare expenditures for persons with CKD. Published 2018. Accessed November 7 2021. https:\/\/www.usrds.org\/media\/1718\/v1_c07_ckd_costs_18_usrds.pdf"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038868"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616011"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.06.009"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30104-9"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30268-7"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13958"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14175"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.2337\/db17-1212"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(17)30069-1"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.123"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12982"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3938-z"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13668"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14443"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.121.055459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T03:37:57Z","timestamp":1715571477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.121.055459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,2,22]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.121.055459"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.121.055459","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"2021-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}